BR112016019837A2 - plasmídeos imunoestimuladores - Google Patents
plasmídeos imunoestimuladoresInfo
- Publication number
- BR112016019837A2 BR112016019837A2 BR112016019837A BR112016019837A BR112016019837A2 BR 112016019837 A2 BR112016019837 A2 BR 112016019837A2 BR 112016019837 A BR112016019837 A BR 112016019837A BR 112016019837 A BR112016019837 A BR 112016019837A BR 112016019837 A2 BR112016019837 A2 BR 112016019837A2
- Authority
- BR
- Brazil
- Prior art keywords
- immunostimulatory plasmids
- methods
- dna sequences
- antibiotic resistance
- plasmids
- Prior art date
Links
- 230000003308 immunostimulating effect Effects 0.000 title abstract 3
- 239000013612 plasmid Substances 0.000 title abstract 3
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- 230000003115 biocidal effect Effects 0.000 abstract 2
- 230000002519 immonomodulatory effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 108091026890 Coding region Proteins 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16771—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461946372P | 2014-02-28 | 2014-02-28 | |
| PCT/EP2015/054131 WO2015128461A1 (en) | 2014-02-28 | 2015-02-27 | Immunostimulatory plasmids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016019837A2 true BR112016019837A2 (pt) | 2017-10-17 |
Family
ID=52598746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016019837A BR112016019837A2 (pt) | 2014-02-28 | 2015-02-27 | plasmídeos imunoestimuladores |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10155950B2 (enExample) |
| EP (1) | EP3110940A1 (enExample) |
| JP (1) | JP6772065B2 (enExample) |
| KR (1) | KR20160122849A (enExample) |
| CN (1) | CN106029867B (enExample) |
| AU (1) | AU2015222102B2 (enExample) |
| BR (1) | BR112016019837A2 (enExample) |
| CA (1) | CA2940794C (enExample) |
| CL (1) | CL2016002146A1 (enExample) |
| CR (1) | CR20160393A (enExample) |
| DO (1) | DOP2016000223A (enExample) |
| IL (1) | IL247065A0 (enExample) |
| MX (1) | MX2016010993A (enExample) |
| PE (1) | PE20170404A1 (enExample) |
| PH (1) | PH12016501705A1 (enExample) |
| RU (1) | RU2740492C2 (enExample) |
| SV (1) | SV2016005263A (enExample) |
| UA (1) | UA118374C2 (enExample) |
| WO (1) | WO2015128461A1 (enExample) |
| ZA (1) | ZA201605495B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2016010993A (es) * | 2014-02-28 | 2017-05-01 | Bayer Animal Health Gmbh | Plasmidos inmunoestimuladores. |
| US10434064B2 (en) | 2014-06-04 | 2019-10-08 | Exicure, Inc. | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| EP3220895B1 (en) | 2014-11-21 | 2022-08-31 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
| KR20180021874A (ko) * | 2015-06-26 | 2018-03-05 | 바이엘 애니멀 헬스 게엠베하 | 시토졸 dna 감시 분자의 조절 방법 |
| TW201718001A (zh) * | 2015-07-31 | 2017-06-01 | 拜耳動物保健有限公司 | 豬物種中增強之免疫反應 |
| KR20180035860A (ko) * | 2015-07-31 | 2018-04-06 | 바이엘 애니멀 헬스 게엠베하 | 수생 종에서의 향상된 면역 반응 |
| PE20190566A1 (es) * | 2016-07-26 | 2019-04-22 | Bayer Animal Health Gmbh | Aumento de la fertilidad en especies bovinas |
| US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| MX2020006243A (es) | 2017-12-15 | 2020-09-03 | Bayer Animal Health Gmbh | Oligonucleotidos inmunoestimulantes. |
| CN109646435B (zh) * | 2019-01-11 | 2021-08-03 | 山东省农业科学院奶牛研究中心 | 厄他培南钠在制备防治牛传染性鼻气管炎药物中的应用 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| US5427791A (en) | 1992-08-05 | 1995-06-27 | Regents Of The University Of Minnesota | Embryonal vaccine against Newcastle disease |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6645933B1 (en) * | 1995-08-01 | 2003-11-11 | Helsinki University Licensing Ltd. Oy | Receptor ligand VEGF-C |
| US5830878A (en) | 1995-06-07 | 1998-11-03 | Megabios Corporation | Cationic lipid: DNA complexes for gene targeting |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US6048535A (en) | 1997-06-12 | 2000-04-11 | Regents Of The University Of Minnesota | Multivalent in ovo avian vaccine |
| US20040247662A1 (en) | 1998-06-25 | 2004-12-09 | Dow Steven W. | Systemic immune activation method using nucleic acid-lipid complexes |
| US6693086B1 (en) | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
| US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
| ATE549032T1 (de) | 1999-03-26 | 2012-03-15 | Vical Inc | Adjuvanzverbindungen zur verbesserung von immunreaktionen auf polynukleotid-basierten impfstoffen |
| US20040002472A1 (en) | 2000-01-21 | 2004-01-01 | Audonnet Jean-Christophe Francis | Vaccination or immunization using a prime-boost regimen |
| US6517218B2 (en) | 2000-03-31 | 2003-02-11 | Relume Corporation | LED integrated heat sink |
| AR035869A1 (es) * | 2001-04-24 | 2004-07-21 | Innogenetics Nv | Proteinas de la envoltura de hcv glicosiladas en la estructura central, un metodo para producir la proteina de envoltura de hcv aislada, una composicion que la comprende, metodo para detectar la presencia de anticuerpos anti-hcv en una muestra, un kit de diagnostico para detectar la presencia de ant |
| JP2004537543A (ja) | 2001-07-02 | 2004-12-16 | ファイザー・プロダクツ・インク | マイコプラズマ・ハイオニューモニエ・ワクチンおよび牛におけるマイコプラズマ・ボビス低減方法 |
| AU2002953015A0 (en) * | 2002-12-02 | 2002-12-12 | Women's And Children's Hospital | Modified lacz gene |
| WO2004093906A1 (en) | 2003-03-26 | 2004-11-04 | Wyeth | Immunogenic composition and methods |
| CA2542099A1 (en) | 2003-10-11 | 2005-04-21 | Inex Pharmaceuticals Corporation | Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
| US20050181035A1 (en) | 2004-02-17 | 2005-08-18 | Dow Steven W. | Systemic immune activation method using non CpG nucleic acids |
| AU2005271247A1 (en) | 2004-08-13 | 2006-02-16 | The Trustees Of The University Of Pennsylvania | Antibiotic resistance free DNA vaccines |
| UY29915A1 (es) | 2005-11-15 | 2007-06-29 | Boehringer Ingelheim Vetmed | Vacuna combinada que comprende un virus atenuado de la diarrea viral bovina |
| TWM297441U (en) | 2006-03-30 | 2006-09-11 | Cheng-Jiun Jian | LED projection light source module |
| US7663229B2 (en) | 2006-07-12 | 2010-02-16 | Hong Kong Applied Science And Technology Research Institute Co., Ltd. | Lighting device |
| MX2009003679A (es) * | 2006-10-06 | 2009-04-23 | Scripps Research Inst | Composicion de adn para provocar una respuesta inmune contra los macrofagos asociados a tumores. |
| US8470560B2 (en) * | 2007-10-03 | 2013-06-25 | The United States Of America As Represented By The Secretary Of The Army | CR-2 binding peptide P28 as molecular adjuvant for DNA vaccines |
| WO2009120811A1 (en) | 2008-03-25 | 2009-10-01 | Juvaris Biotherapeutics, Inc. | Enhancement of an immune response by administration of a cationic lipid-dna complex (cldc) |
| US8815255B2 (en) | 2008-10-31 | 2014-08-26 | Boehringer Ingelheim Vetmedica, Inc. | Use of Mycoplasma bovis antigen |
| DK2429581T3 (en) | 2009-05-14 | 2015-11-09 | Bayer Ip Gmbh | Improved immune responses in birds |
| PT2654785T (pt) | 2010-12-22 | 2019-06-25 | Bayer Ip Gmbh | Resposta imunitária melhorada em espécies bovinas |
| CL2011000065A1 (es) | 2011-01-11 | 2011-04-15 | Univ Concepcion | Formulacion veterinaria para la prevencion y eliminacion de infeccion por cepas de e. coli stec, que comprende un plasmido recombinante que codifica un factor de virulencia y liposoma cationico como vehiculo, uso de dicha formulacion para tratar preferentemente bovinos y porcinos. |
| MX2016010993A (es) * | 2014-02-28 | 2017-05-01 | Bayer Animal Health Gmbh | Plasmidos inmunoestimuladores. |
-
2015
- 2015-02-27 MX MX2016010993A patent/MX2016010993A/es unknown
- 2015-02-27 BR BR112016019837A patent/BR112016019837A2/pt not_active Application Discontinuation
- 2015-02-27 PE PE2016001534A patent/PE20170404A1/es not_active Application Discontinuation
- 2015-02-27 US US14/633,920 patent/US10155950B2/en active Active
- 2015-02-27 CR CR20160393A patent/CR20160393A/es unknown
- 2015-02-27 AU AU2015222102A patent/AU2015222102B2/en not_active Ceased
- 2015-02-27 CN CN201580010413.0A patent/CN106029867B/zh active Active
- 2015-02-27 CA CA2940794A patent/CA2940794C/en active Active
- 2015-02-27 RU RU2016138321A patent/RU2740492C2/ru active
- 2015-02-27 EP EP15707606.8A patent/EP3110940A1/en not_active Ceased
- 2015-02-27 KR KR1020167026797A patent/KR20160122849A/ko not_active Withdrawn
- 2015-02-27 WO PCT/EP2015/054131 patent/WO2015128461A1/en not_active Ceased
- 2015-02-27 UA UAA201609729A patent/UA118374C2/uk unknown
- 2015-02-27 JP JP2016554261A patent/JP6772065B2/ja not_active Expired - Fee Related
-
2016
- 2016-08-02 IL IL247065A patent/IL247065A0/en unknown
- 2016-08-08 ZA ZA2016/05495A patent/ZA201605495B/en unknown
- 2016-08-24 CL CL2016002146A patent/CL2016002146A1/es unknown
- 2016-08-26 SV SV2016005263A patent/SV2016005263A/es unknown
- 2016-08-26 DO DO2016000223A patent/DOP2016000223A/es unknown
- 2016-08-26 PH PH12016501705A patent/PH12016501705A1/en unknown
-
2018
- 2018-04-25 US US15/962,414 patent/US10851379B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL247065A0 (en) | 2016-09-29 |
| RU2016138321A3 (enExample) | 2018-11-12 |
| CN106029867B (zh) | 2020-02-14 |
| CL2016002146A1 (es) | 2017-08-04 |
| AU2015222102B2 (en) | 2021-08-19 |
| EP3110940A1 (en) | 2017-01-04 |
| US20150267201A1 (en) | 2015-09-24 |
| KR20160122849A (ko) | 2016-10-24 |
| CA2940794A1 (en) | 2015-09-03 |
| RU2740492C2 (ru) | 2021-01-14 |
| US20180312842A1 (en) | 2018-11-01 |
| UA118374C2 (uk) | 2019-01-10 |
| CA2940794C (en) | 2022-05-31 |
| PE20170404A1 (es) | 2017-05-14 |
| JP6772065B2 (ja) | 2020-10-21 |
| US10851379B2 (en) | 2020-12-01 |
| ZA201605495B (en) | 2022-08-31 |
| JP2017512202A (ja) | 2017-05-18 |
| DOP2016000223A (es) | 2016-09-30 |
| CN106029867A (zh) | 2016-10-12 |
| US10155950B2 (en) | 2018-12-18 |
| RU2016138321A (ru) | 2018-03-30 |
| AU2015222102A1 (en) | 2016-08-18 |
| CR20160393A (es) | 2017-12-14 |
| PH12016501705A1 (en) | 2016-10-03 |
| MX2016010993A (es) | 2017-05-01 |
| WO2015128461A1 (en) | 2015-09-03 |
| SV2016005263A (es) | 2018-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016019837A2 (pt) | plasmídeos imunoestimuladores | |
| CY1123823T1 (el) | Βελτιωμενες συνθεσεις τ κυτταρων | |
| CY1124004T1 (el) | Υποδορια σκευασματα αντισωματων αντι-cd38 και οι χρησεις τους | |
| ME03463B (me) | Kompozicije koje sadrže bakterijske sojeve | |
| LT3307288T (lt) | Kompozicijos, apimančios bakterijų kamienus | |
| MX2017006695A (es) | Variantes de subtilasa y polinucleotidos que las codifican. | |
| EA201300585A1 (ru) | Иммуномодулирующие олигонуклеотиды | |
| CY1119093T1 (el) | Ανοσο-ρυθμιστικο προγονικο (imp) κυτταρο | |
| CN106715699A8 (zh) | 用于减弱抗病毒转移载体免疫应答的方法和组合物 | |
| IL250388B (en) | Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells | |
| MX2017014469A (es) | Constructos de expresion y metodos para diseñar geneticamente levadura metilotrofica. | |
| PH12016500165A1 (en) | Compositions and methods related to isolated endophytes | |
| ME03584B (me) | Kompozicije koje sadrže sojeve bakterija | |
| ME03595B (me) | Kompozicije koje sadrže bakterijske sojeve | |
| ME03562B (me) | Kompozicije koje sadrže bakterijske sojeve | |
| MX2021010668A (es) | Proteinas de fusion de citoquinas. | |
| IL247469A0 (en) | Methods for refining conjugates based on alpha il-15/il-15r, preparations containing products produced in this way and their uses | |
| MY181175A (en) | Therapeutic hpv16 vaccines | |
| MX2017016401A (es) | Composiciones inmunogenas. | |
| EP4480544A3 (en) | Immunomodulatory compositions andmethods of use thereof | |
| PH12014502855A1 (en) | Attenuated streptococcus suis vaccines and methods of making and use thereof | |
| MX378857B (es) | Celulas huespedes modificadas y usos de las mismas. | |
| ZA201603187B (en) | Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors | |
| MX2017009682A (es) | Composiciones de caldo y su uso como prebioticos. | |
| MX2019006090A (es) | Metodos para mejorar la respuesta inmune con everolimus, dactolisib o ambos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |
|
| B25H | Request for change of headquarter rejected |
Owner name: BAYER ANIMAL HEALTH GMBH (DE) Free format text: INDEFERIDO O PEDIDO DE ALTERACAO DE SEDE CONTIDO NA PETICAO 870240023600 DE 19/03/2024 DEVIDO AO DESPACHO PUBLICADO NA RPI 2790 DE 25/06/2024. |
|
| B25E | Requested change of name of applicant rejected |
Owner name: BAYER ANIMAL HEALTH GMBH (DE) Free format text: INDEFERIDO O PEDIDO DE ALTERACAO DE NOME CONTIDO NA PETICAO 870240023600 DE 19/03/2024 DEVIDO AO DESPACHO PUBLICADO NA RPI 2790 DE 25/06/2024. |